A randomized trial on the effect of oral combined estradiol and drospirenone on glucose and insulin metabolism in healthy menopausal women with a normal OGTT

Menopause is often associated with a central accumulation of body fat [1]. This may provoke insulin resistance, leading to hyperinsulinemia [2]. An increased insulin level is a risk factor for diabetes [3,4] and cardiovascular disease [5]. Moreover, the Women ’s Health Initiative (WHI) trial revealed that hyperinsulinemia is an independent risk factor for postmenopausal breast cancer [6]. As obese postmenopausal women have higher levels of estrogen, it is believed that estrogens are linked to increased breast cancer risk.

Source: Maturitas - April 28, 2020 Category: Primary Care Authors: H Depypere, A Dierickx, Velde F Van de, F Stanczyk, L Ottoy, J Delanghe, B Lapauw Source Type: research